Posted by Clinical trial NCT07079761 may help us understand treatable factors that increase risk for chronic or treatment-resistant Post Traumatic Stress Disorder (PTSD) and PTSD-related depression. The results also tell us whether treatments that increase Allopregnalonene (Allo) might help prevent or treat PTSD. IV Allo (at much higher doses than used in this study) is currently FDA-approved for treatment of postpartum depression, supporting the potential for this research to spur development of Allo as a new treatment for PTSD.
The applied drug: Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion.
Study start: 04. 08. 2025
The estimated completion of the trial: 30. 04. 2027.